Impact of advanced prostatic cancer treatment on quality of life and sexual function

INTRODUCTION

Prostate cancer (PC) is the most common nonskin cancer in the United States, with an estimated 268,490 new cases associated with 34,500 deaths in 2022.1 When small and located only in the prostate, PC can be clinically followed up with biopsies and periodic imaging exams or treated with curative intent, through prostatectomy and radiotherapy (RT).2 Even after a properly treated cancer limited to the prostate, approximately 30% of PC persist.3 There are several criteria to define recurrence prostate cancer (RPC) after treatment, being the prostate-specific antigen (PSA) level being the most used and studied.4

Quality of life is a multidimensional concept, that considers the patient’s subjective regards. About themselves, considering multiple aspects of their real and desired lives. Studies on quality of life include health, social, mental, and physical characteristics.5 Most studies on quality of life in PC refer to the initial stage of the disease and compare various treatments, with a focus on isolated prostatectomy or combined with RT and hormone therapy. According to Chen et al. (2017),6 surgical procedures on prostate are frequently associated with urinary incontinence (UI) and sexual dysfunction. Other treatments such as RT are also responsible for sexual dysfunctions, UI, urinary infections, cystitis, and severe dermatitis, as well as digestive complications, including diarrhea, hematochezia, and strictures.7 To prevent these adversities and maintain quality of life, the option of not treating PC has been accepted as an active follow-up approach.8 Most studies have not revealed any difference in quality of life after different treatments, which may be isolated or combined.9

Considering RPC after different managements protocols, many new treatments are indicated to prevent PC growth and metastasis. These therapies do not cure patients, but control complications, such as bone pain, urinary disorders, infections, and digestive disorders, which worsen the quality of life. On the other hand, the various treatments for RPC are accompanied by adverse effects, which also interfere with quality of life.

MATERIAL AND METHODS

This work was approved by the Ethics Committee for Human Research - CAAE: 4149021.1.0000.5140. All patients were invited to participate in this study, and they signed their agreement to the Free and Informed Consent Terms. This study was carried out on 200 consecutive patients with RPC after treatment at the Oncology Services of the Municipal Health Department, Belo Horizonte, Brazil. The RPC was established by persistence of PSA after radical prostatectomy or after radiotherapy any PSA increase >2ng/ml higher than the PSA nadir, regardless of the nadir value.10 The adenocarcinoma was confirmed by needle biopsy guided by ultrasound. The interviews with the patients occurred about symptoms before any treatment and six months after the last treatment for RPC, to avoid the immediate and transient effects of the treatment. Patients were distributed into the following four groups, according to the treatments they underwent: group 1 (N=35) – open prostatectomy and androgen deprivation hormone therapy (ADHT); group 2 (N=69): open prostatectomy combined with RT and ADHT; group 3 (N=29): only ADHT; group 4 (N=67): RT combined with ADHT.

This study assessed the quality of life outcomes in the four groups of treated patients with biochemical recurrence, comparing the results before and after each treatment. The quality of life was assessed by means of the European Quality of Life Questionnaire (EQ-5D5L), a questionnaire validated internationally and in Brazil for five dimensions (mobility, self-care, usual activities, pain, and emotional disorders).11 In addition to these parameters, the presence of urinary infection, hematuria, hematochezia, UI, and urethral stricture were investigated. Recurrent urinary tract infection was considered when there were more than two episodes in one year.12 Hematuria was confirmed by routine urinary examination. Hematochezia was confirmed by fecal occult blood test. UI was considered when there was a need to use more than one diaper per day.13 Urethral stricture was assessed by delayed onset of voiding, with a fine stream and multiple voiding interruptions.14 Each dimension and complication was classified according to intensity as follows: 1 (no complaints), 2 (few complaints), 3 (moderate complaints), 4 (intense complaints), and 5 (very intense complaint).15

Erectile dysfunction (ED) was uniformly assessed in 25 randomized patients from each group by means of the International Index of Erectile Function (IIEF-5), comparing the results before and after each treatment. Erection and sexual satisfaction were classified by frequency 0 (never), 1 (rarely), 2 (moderately), 3 (frequently), 4 (almost always), and 5 (always).16

Nominal variables were expressed as frequencies and percentages, and numerical variables such as age, EQ-5D5L domains and IIEF-5 assessment, which did not have a normal Gaussian distribution, were calculated using the nonparametric Kruskal-Wallis test. In comparing the medians between two independent groups, referring to age and IIEF-5 data, the nonparametric Mann-Whitney test with Bonferroni correction was used. The association of hypotheses between categorical variables from different groups was verified by applying Fisher’s exact test. All analyses were performed using SPSS 23 software (Statistical Package for the Social Sciences 23) and the significance level considered was greater than 95%, corresponding to p<0.05.

RESULTS

The median age of patients in group 1 was 71 (65 to 75) years, in group 2 it was 68 (62 to 72) years, in group 3 it was 69 (63 to 76) years and in group 4 it was 72 (67 to 78) years. In the four groups, the age range was similar and the single difference between the groups was that the age was lower in group 2 than in group 4 (p<0.041), but without significance for this study.

According to the EQ-5D5L, the mobility of patients after the treatments studied was worse in group 2. It should be noted that most patients in all groups had no mobility limitation and no patient suffered severe limitation (Table 1). Self-care was assessed by the ability to shower alone and get dressed. Groups 2 and 3 had the worst results, with most patients in all groups having up to moderate limitations in self-care (Table 1). There was no difference between the four groups in routine activities, although group 2 had greater difficulties (Table 1). Pain was also not different between the four groups. On the other hand, emotional disorders were less apparent in group 1 and more intense in group 3 (Table 1).

UI occurred in all four groups: in group 1 (20.0%), group 2 (30.4%), group 3 (6.9%), and group 4 (7.5%). The results of group 2 were worse than the other three groups (p=0.002). Other complications were observed, including urethral stricture, urinary infection, hematuria, and hematochezia. All of them occurred in a few patients and there was no difference between groups, probably due to the reduced number of cases with complications (Table 2).

According to the responses to the IIEF-5 questionnaire, there was a worsening on sexual function in all four treatments, with no difference among them. There was erection dysfunction and sexual dissatisfaction after all treatments, and with greater severity in the groups submitted to prostatectomy. All patients had erection and sexual satisfaction, even if rarely, and no patient showed erection and sexual satisfaction always (Table 3).

DISCUSSION

This study adopted the EQ-5D5L questionnaire to assess the quality of life of patients with RPC, as it is a standardized protocol accepted in the Brazilian literature, with reliable results. Studies on quality of life in patients with RPC were not found in the literature. Considering that RPC survival, regardless of treatment, exceeds ten years in 98% of patients, quality of life becomes relevant.17 The treatments aim to control the disease, even if it is not cured, preserving or improving the quality of life.

Dimensions of the European Quality of Life Questionnaire, in the four types of treatment for remaining prostate cancer, presented as number of cases (N) and their percentage in each group.

Dimension

Group 1 (N = 35) Before After N (%) N(%)

Group 2 (N = 69) Before After N (%) N(%)

Group 3 (N = 29) Before After N (%) N(%)

Group 4 (N = 67) Before After N (%) N(%)

P

Mobility

1

34(97) 33(94.3)

49(71) 50(72.5)

24(83) 24(82.8)

60(89.6) 60(89.6)

0.014

2

1(3) 2(5.7)

19(27) 18(26.1)

5(17) 4(13.8)

7(10.4) 7(10.4)

0.020

3

0(0) 0(0)

1(2) 1(1.4)

0(0) 1(3.4)

0(0) 0(0)

0.299

Self-care

1

35(100) 8(22.9)

53(77) 8(11.6)

20(69) 8(27.6)

52(78) 12 (17.9)

0.232

2

0(0) 18(51.4)

15(22) 27(39.1)

9(31) 14(48.3)

11(16) 42(62.7)

0.055

3

0(0) 9(25.7)

1(1) 24(34.8)

0(0) 6(20.7)

4(6) 12(17.9)

0.138

4

0(0) 0(0)

0(0) 8(11.6)

0(0) 1(3.4)

0(0) 1(1.5)

0.025

5

0(0) 0(0)

0(0) 2(2.9)

0(0) 0(0)

0(0) 0(0)

0.646

Activities

1

29(82) 23(65.7)

60(87) 36(52.2)

14(48) 20(69)

52(78) 52(77.6)

0.019

2

5(14) 6(17.1)

7(10) 10(14.5)

10(34) 5(17.2)

10(15) 4(6)

0.246

3

1(4) 5(14.3)

2(3) 18(26.1)

4(14) 2(7,0)

4(6) 11(16.4)

0.116

4

0(0) 1(2.9)

0(0) 5(7.2)

1(4) (3.4)

1(1) 0(0)

0.102

5

0(0) 0(0)

0(0) 0(0)

0(0) 1(3.4)

0(0) 0(0)

0.145

Pain

1

19(54) 14(40)

42(61) 27(39.1)

13(45) 11(37.9)

31(46) 30(44.8)

0.891

2

15(42) 17(48.5)

22(32) 25(36.2)

9(31) 9(31)

21(31) 24(35.8)

0.480

3

1(4) 3(8.6)

5(7) 10(14.5)

5(17) 2(6.9)

10(15) 8(11.9)

0.750

4

0(0) 0(0)

0(0) 3(4.3)

2(7) 3(10.4)

5(8) 3(4.5)

0.260

5

0(0) 1(2.9)

0(0) 4(5.9)

0(0) 4(13.8)

0(0) 2(3.0)

0.200

Emotional disorders

1

34(97) 33(94.2)

65(94) 57(82.6)

25(86) 20 (69.0)

64(96) 60 (89.5)

0.022

2

1(3) 1(2.9)

3(4) 11(15.9)

5(7) 5(17.3)

2(3) 4(6.0)

0.061

3

0(0) 0(0)

1(2) 0(0)

0(0) 1(3.4)

0(0) 0(0)

0.145

4

0(0) 1(2.9)

0(0) 1(1.5)

2(7) 3(10.3)

1(1) 3(4.5)

0.215

Group 1 – prostatectomy and androgen deprivation hormone therapy (ADHT); Group 2 – prostatectomy associated with radiotherapy (RT) and ADHT; Group 3 – ADHT alone; Group 4 – RT associated with ADHT. Before and After treatment. Dimensions intensity: 1(without complaint), 2(little complaint ), 3 (moderate complaint), 4 (intense complaint) e 5 (very intense complaint). P corresponding to Fisher’s exact test.

According to the analysis of the EQ-5D5L domains, the results of this study revealed that all treatments interfere with mobility and are accompanied by difficultiesinself-care, withrestrictionsonthepatients’ usual activities. Restrictions are moderate and many of them are result from the RPC itself associated with advanced age and metastases. Comorbidities such as fatigue due to cardiopulmonary failure, sarcopenia and osteoporosis are also responsible for greater limitations in the quality of life.18 More aggressive treatments, mainly the open prostatectomy associated with RT worsen the limitations to mobility and self-care, as well as UI, which negatively interfere on the quality of life.19

The results of this work contradict the publication by Downing et al. (2019),20 who assign the worsening in quality of life only to the advanced cancer stage. UI is the most frequent complication after prostatectomy, and it is present in 4% to 69% of the patients submitted to prostatectomy, depending on the surgical methods and experience of the surgeons.21 This adversity, sometimes definitive, despite not being life threatening, is harmful to the quality of life. UI is, in general, a consequence of surgical injury to the neurovascular plexus, including the pudendal nerve. This injury is more frequent in open prostatectomies performed by less skilled surgeons.22 On the other hand, in conservative treatments, such as RT and hormone therapy, UI is rare (1% to 5%).23 This complication is also associated with dysfunctions resulting vesical sphincter hypotonia due to aging.

Late urological and digestive manifestations after treatments for remaining prostate cancer. Results are presented as number of cases (N) and their percentage in each group.

Clinical manifestations

Group 1 (N = 35) Before After N (%) N(%)

Group 2 (N = 69) Before After N (%) N(%)

Group 3 (N = 29) Before After N (%) N(%)

Group 4 (N = 67) Before After N (%) N(%)

P

Urinary incontinence

0(0) 7(20,0)

0(0) 21(30,4)

0(0) 2 (6,9)

0(0) 5 (7,5)

0,002

Urethral stricture

0(0) 2(5.7)

0(0) 7 (10.1)

0(0) 4(13.8)

0(0) 7(10.4)

0.769

Urinary infection

0(0) 1(2.9)

0(0) 2(2.9)

0(0) 0(0)

0(0) 1(1.5)

1.000

Hematuria

0(0) 0(0)

0(0) 5(7.2)

0(0) 1(3.4)

0(0) 1(1.5)

0.209

Hematochezia

0(0) 0(0)

0(0) 4(5.8)

0(0) 0(0)

0(0) 2(3.0)

0.389

Group 1 – prostatectomy and androgen deprivation hormone therapy (ADHT); Group 2 – prostatectomy associated with radiotherapy (RT) and ADHT; Group 3 – ADHT alone; Group 4 – RT associated with ADHT; Before and After treatment P corresponding to Fisher’s exact test.

Obesity, neurological disorders and alcoholism may curse with UI, even without cancer treatment. It is important to point out that group 1, open prostatectomy and ADHT, were formed with patients that probably suffered surgical treatment and patient didn’t agree to treat with salvage radiotherapy or new exams revealed new lesions that didn’t justify any radiotherapy. Moreover, group 3 formed with patients that received only ADTH differs from the others because they were on slightly more advanced stages than other groups. Notwithstanding, we observed that patients in group 3 with more advanced diseased produced any difference on the final results because the biggest loss in quality of life maintained with group 2 (prostatectomy combined with RT and ADHT).

Anxiety and depression are psychiatric manifestations often attributed to cancer treatments, but they are rarely diagnosed by psychiatrists. The real feeling is generally an emotional disorder, most often sadness, which is due to the cancer, its complications, aggressive treatment, and social limits. In this study, emotional disorders were more frequent after TAD, probably due to adverse drug effects in more advanced stages of RPC. According to the literature, hormonal blockade for RPC has a 23% higher risk of adverse emotional manifestations and dementia states, which may be treated with testosterone.24 Emotional adversities occur more frequently in elderly people who live in isolation and especially in the presence of comorbidities.25

In this study, the four treatments impaired the sexual performance. Prostatectomy and RT were the treatments more frequently associated with sexual dysfunction and worsening of quality of life. Sexual dysfunction occurs in 30% to 50% of patients with RPC, with an increase in prevalence with advancing age and the presence of comorbidities, such as diabetes mellitus, obesity, heart disease, and restrictive lung diseases.26 It should be noted in this study that more than 40% of patients undergoing prostatectomy preserved their sexual ability and more than half of patients undergoing RT reported erections with sufficient rigidity to establish satisfactory sexual performance, similar to other studies.27 It should be noted that the literature reports less sexual dysfunction, UI and effect on quality of life after prostatectomies performed by minimally invasive methods and with the aid of robotic equipment.28 However, in the series all patients underwent open prostatectomy.

Male libido is influenced by testosterone receptors, which are essential for penile smooth muscle relaxation promoting erection. RT modifies the penile architecture, with reduction of smooth muscle and its replacement by fibrous tissue, compromising erection.[29]

CONCLUSION

Open prostatectomy is associated with complications, which are responsible for a worse quality of life due to mobility limitations, difficulty in self-care, urinary incontinence, and sexual dysfunction. All these adversities worsen when the surgery is combined with radiotherapy and androgen deprivation hormone therapy.

Comparison between the values of the International Erectile Dysfunction Index Questionnaire from the six months prior to this study, in the four types of treatment for remaining prostate cancer, presented as number of cases (N) and their percentage in each group composed of 25 patients.

Variable

Group 1 (N = 25) Before After N (%) N(%)

Group 2 (N = 25) Before After N (%) N(%)

Group 3 (N = 25) Before After N (%) N(%)

Group 4 (N = 25) Before After N (%) N(%)

P

Frequency of rigid erection maintenance

0.031

1

0(0) 12(48)

0(0) 16(64)

0(0) 10(40)

1(4) 10(40)

2

0(0) 13(52)

0(0) 9(36)

0(0) 10(40)

4(16) 0(40)

3

1(4) 0(0)

0(0) 0(0)

5(20) 3(12)

0(0) 0(0)

4

6(24) 0(0)

6(24) 0(0)

15(60) 2(8)

9(36) 5(20)

5

18(72) 0(0)

19(76) 0(0)

5(20) 0(0)

11(44) 0(0)

Degree of confidence in erections with sufficient rigidity

0.049

1

0(0) 11(44)

0(0) 16(64)

0(0) 10(40)

0(0) 10(40)

2

0(0) 13(52)

0(0) 9(36)

0(0) 10(40)

2(8) 10(40)

3

1(4) 0(0)

0(0) 0(0)

5(20) 3(12)

0(0) 0(0)

4

6(24) 0(0)

6(24) 0(0)

15(60) 2(8)

11(44) 5(20)

5

18(72) 0(0)

19(76) 0(0)

5(20) 0(0)

12(48) 0(0)

How many erections had sufficient rigidity during intercourse

0.017

1

0(0) 10(40)

0(0) 16 (64)

0(0) 11(44)

2(8) 10(40)

2

0(0) 15(60)

0(0) 9 (36)

0(0) 9(36)

3(12) 10(40)

3

0(0) 0(0)

0(0) 0(0)

5(20) 3(12)

0(0) 0(0)

4

6(24) 0(0)

6(24) 0(0)

15(60) 2(8)

14(56) 5(20)

5

19(76) 0(0)

19(76) 0(0)

5(20) 0(0)

6(24) 0(0)

Maintain an erection with sufficient rigidity during intercourse

0.017

1

10 (40)

0(0) 16(64)

0(0) 11(44)

1(4) 10(40)

2

15 (60)

0(0) 9(36)

0(0) 9(36)

1(4) 10(40)

3

0(0) 0(0)

0(0) 0(0)

4(16) 3(12)

0(0) 0(0)

4

6(24) 0(0)

6(24) 0(0)

13(52) 2(8)

12(48) 5(20)

5

19(76) 0(0)

19(76) 0(0)

8(32) 0(0)

11(44) 0(0)

Patient satisfaction during sexual intercourse

0.018

1

0(0) 10(40)

0(0) 16(64)

0(0) 10(40)

2(8) 10(40)

2

0(0) 15(60)

0(0) 9(36)

0(0) 10(40)

2(8) 10(40)

3

0(0) 0(0)

0(0) 0(0)

4(16) 3(12)

0(0) 0(0)

4

6(24) 0(0)

6(24) 0(0)

13(52) 2(8)

11(44) 5(20)

5

19(76) 0(0)

19(76) 0(0)

8(32) 0(0)

10(40) 0(0)

AUTHORS’ CONTRIBUTIONS

FPM Collection and assembly of data, Data analysis and interpretation, Final approval of manuscript, Manuscript writing, Provision of study materials or patient

AP Conception and design, Data analysis and interpretation, Final approval of manuscript

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Authors

About the Journal

Journal: Brazilian Journal of Oncology

DOI: 10.1055/s-00059887

e-issn: 2526-8732

Publisher: Thieme Revinter Publicações Ltda.

Publisher address: Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

No citations found for this article.

References

1. Siegel, RL and Miller, KD and Fuchs, HE and Jemal, A. Cancer statistics, 2022. CA Cancer J Clin [online]. 2022, vol. 72, p. 7-33. https://doi.org/10.3322/caac.21708 Ver referência

2. Klotz, L. Active surveillance for intermediate risk prostate cancer. Curr Urol Rep [online]. 2017, vol. 18, p. 80. https://doi.org/10.1007/s11934-017-0726-3 Ver referência

3. Pound, CR and Partin, AW and Eisenberger, MA and Chan, DW and Pearson, JD and Walsh, RRPC. Natural history of progression after PSA. J Am Med Assoc [online]. 1999, vol. 281, p. 1591-7. https://doi.org/10.1001/jama.281.17.1591 Ver referência

4. Matsumoto, K and Niwa, N and Hattori, S and Takeda, T and Morita, S and Kosaka, T. Establishment of the optimal follow-up schedule after radical prostatectomy. Urol Oncol [online]. 2018, vol. 36, p. e341. https://doi.org/10.1016/j.urolonc.2018.04.003 Ver referência

5. Van Der Veen, JH and Van Andel, G and Kurth, KH. Quality-of-life assessment in bladder cancer. World J Urol [online]. 1999, vol. 17, p. 219-24. https://doi.org/10.1007/s003450050136 Ver referência

6. Chen, RC and Basak, R and Meyer, AM and Kuo, TM and Carpenter, WR and Agans, RP. Association between choice of radical prostatectomy, external beam radiotherapy, brachytherapy, or active surveillance and patient-reported quality of life among men with localized prostate cancer. JAMA [online]. 2017, vol. 317, p. 1141-50. https://doi.org/10.1001/jama.2017.1652 Ver referência

7. Lardas, M and Liew, M and Van den Bergh, RC and De Santis, M and Bellmunt, J and Van den Broeck, T. Quality of life outcomes after primary treatment for clinically localised prostate cancer. Eur Urol [online]. 2017, vol. 72, p. 869-85. https://doi.org/10.1016/j.eururo.2017.06.035 Ver referência

8. Bellardita, L and Valdagni, R and Van den Bergh, R and Randsdorp, H and Repetto, C and Venderbos, LD. How does active surveillance for prostate cancer affect quality of life?. Eur Urol [online]. 2015, vol. 67, p. 637-45. https://doi.org/10.1016/j.eururo.2014.10.028 Ver referência

9. Vernooij, RW and Lancee, M and Cleves, A and Dahm, P and Bangma, CH and Aben, KK. Radical prostatectomy versus deferred treatment for localised prostate cancer. Cochrane Database Syst Rev [online]. 2020, vol. 6, p. CD006590. https://doi.org/10.1002/14651858 Ver referência

10. Van den Broeck, T and Van den Bergh, RCN and Briers, E and Cornford, P and Cumberbatch, M and Tilki, D. Biochemical recurrence in prostate cancer: the european association of urology prostate cancer guidelines panel recommendations. Eur Urol Focus [online]. 2020, vol. 6, p. 231-4. https://doi.org/10.1016/j.euf.2019.06.004 Ver referência

11. Kind, P and Pickard, AS. Interim scoring for the EQ-5D-5L. [online]. 2012, vol. 15, p. 708-15. https://doi.org/10.1016/j.jval.2012.02.008 Ver referência

12. Butler, CC and Hawking, MK and Quigley, A and McNulty, CA. Incidence, severity, help seeking and management of uncomplicated urinary tract infection. Br J Gen Pract [online]. 2015, vol. 65, p. e702-e7. https://doi.org/10.3399/bjgp15X686965 Ver referência

13. Averbeck, MA and Woodhouse, C and Comiter, C and Bruschini, H and Hanus, T and Herschorn, S. Surgical treatment of post-prostatectomy stress urinary incontinence in adult men. Neurourol Urodyn [online]. 2019, vol. 38, p. 398-406. https://doi.org/10.1002/nau.23845 Ver referência

14. Cotta, BH and Buckley, JC. Endoscopic treatment of urethral stenosis. Urol Clin North Am [online]. 2017, vol. 44, p. 19-25. https://doi.org/10.1016/j.ucl.2016.08.008 Ver referência

15. Gamst-Klaussen, T and Lamu, AN. Does the EQ-5D usual activities dimension measure what it intends to measure?. Qual Life Res [online]. 2020, vol. 29, p. 2553-62. https://doi.org/10.1007/s11136-020-02501-w Ver referência

16. Rosen, RC and Cappelleri, JC and Gendrano, N. The International Index of Erectile Function (IIEF): a state-of-the-science review. Int J Impot Res [online]. 2002, vol. 14, p. 226-44. https://doi.org/10.1038/sj.ijir.3900857 Ver referência

17. Shevach, J and Weiner, A and Morgans, AK. Quality of life-focused decision-making for prostate cancer. Curr Urol Rep [online]. 2019, vol. 20, p. 57. https://doi.org/10.1007/s11934-019-0924-2 Ver referência

18. Magee, DE and Singal, RK. Androgen deprivation therapy: indications, methods of utilization, side effects and their management. Can J Urol [online]. 2020, vol. 27, p. 11-6.

19. Neal, DE and Metcalfe, C and Donovan, JL and Lane, JA and Davis, M and Walsh, EI. Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the ProtecT randomised controlled trial according to treatment received. Eur Urol [online]. 2020, vol. 77, p. 320-30. https://doi.org/10.1016/j.eururo.2019.10.030 Ver referência

20. Downing, A and Wright, P and Hounsome, L and Selby, P and Wilding, S and Watson, E. Quality of life in men living with advanced and localised prostate cancer in the UK. Lancet Oncol [online]. 2019, vol. 20, p. 436-47. https://doi.org/10.1016/S1470-2045(18)30780-0 Ver referência

21. Heesakkers, J and Farag, F and Bauer, RM and Sandhu, J and De Ridder, D and Stenzl, A. Pathophysiology and contributing factors in postprostatectomy incontinence. Eur Urol [online]. 2017, vol. 71, p. 936-44.

22. Schifano, N and Capogrosso, P and Tutolo, M and Dehò, F and Montorsi, F and Salonia, A. How to prevent and manage post-prostatectomy incontinence. World J Mens Health [online]. 2021, vol. 39, p. 581-97. https://doi.org/10.5534/wjmh.200114 Ver referência

23. Cozzarini, C and Rancati, T and Palorini, F and Avuzzi, B and Garibaldi, E and Balestrini, D. Patient-reported urinary incontinence after radiotherapy for prostate cancer. Radiother Oncol [online]. 2017, vol. 125, p. 101-6. https://doi.org/10.1016/j.radonc.2017.07.029 Ver referência

24. Izard, JP and Siemens, DR. Androgen deprivation therapy and mental health: impact on depression and cognition. Eur Urol Focus [online]. 2020, vol. 6, p. 1162-4. https://doi.org/10.1016/j.euf.2019.11.010 Ver referência

25. Dinh, KT and Reznor, G and Muralidhar, V and Mahal, BA and Nezolosky, MD and Choueiri, TK. Association of androgen deprivation therapy with depression in localized prostate cancer. J Clin Oncol [online]. 2016, vol. 34, p. 1905-12. https://doi.org/10.1200/JCO.2015.64.1969 Ver referência

26. Steinsvik, EA and Axcrona, K and Dahl, AA and Eri, LM and Stensvold, A and Fossa, SD. Can sexual bother after radical prostatectomy be predicted preoperatively?. BJU Int [online]. 2012, vol. 109, p. 1366-74. https://doi.org/10.1111/j.1464-410X.2011.10598.x Ver referência

27. Resnick, MJ and Barocas, DA and Morgans, AK and Phillips, SE and Chen, VW and Cooperberg, MR. Contemporary prevalence of pretreatment urinary, sexual, hormonal, and bowel dysfunction. Cancer [online]. 2014, vol. 120, p. 1263-71. https://doi.org/10.1002/cncr.28563 Ver referência

28. Bhat, KRS and Raghunath, SK and Srivatsa, N and Tejus, C and Vishruth, K and Kumar, RA. Outcomes of minimally invasive radical prostatectomy-a contemporary review. Indian J Surg Oncol [online]. 2020, vol. 11, p. 580-8. https://doi.org/10.1007/s13193-020-01125-3 Ver referência

30. Corona, G and Filippi, S and Comelio, P and Bianchi, N and Frizza, F and Dicuio, M. Sexual function in men undergoing androgen deprivation therapy. Int J Impot Res [online]. 2021, vol. 33, p. 439-47. https://doi.org/10.1038/s41443-021-00418-7 Ver referência

Article images

See where this article was accessed

Dados de acesso insuficientes para visualização no mapa.